Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2013 1
2014 1
2016 1
2019 1
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα.
Poirier N, Baccelli I, Belarif L, Abès R, Teppaz G, Mary C, Poli S, Fromond C, Girault I, Pengam S, Soma E, De Sa F, Conduzorgues JP, Braudeau C, Josien R, Volckaert B, Costantini D, Corallo F. Poirier N, et al. Among authors: teppaz g. J Immunol. 2023 Mar 15;210(6):753-763. doi: 10.4049/jimmunol.2200635. J Immunol. 2023. PMID: 36734626 Clinical Trial.
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.
Drouin M, Saenz J, Gauttier V, Evrard B, Teppaz G, Pengam S, Mary C, Desselle A, Thepenier V, Wilhelm E, Merieau E, Ligeron C, Girault I, Lopez MD, Fourgeux C, Sinha D, Baccelli I, Moreau A, Louvet C, Josien R, Poschmann J, Poirier N, Chiffoleau E. Drouin M, et al. Among authors: teppaz g. Sci Adv. 2022 Nov 16;8(46):eabo7621. doi: 10.1126/sciadv.abo7621. Epub 2022 Nov 18. Sci Adv. 2022. PMID: 36399563 Free PMC article.
Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.
Trilleaud C, Gauttier V, Biteau K, Girault I, Belarif L, Mary C, Pengam S, Teppaz G, Thepenier V, Danger R, Robert-Siegwald G, Néel M, Bruneau S, Glémain A, Néel A, Poupon A, Mosnier JF, Chêne G, Dubourdeau M, Blancho G, Vanhove B, Poirier N. Trilleaud C, et al. Among authors: teppaz g. Sci Adv. 2021 Apr 2;7(14):eabd1453. doi: 10.1126/sciadv.abd1453. Print 2021 Apr. Sci Adv. 2021. PMID: 33811066 Free article.
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N. Gauttier V, et al. Among authors: teppaz g. J Clin Invest. 2020 Nov 2;130(11):6109-6123. doi: 10.1172/JCI135528. J Clin Invest. 2020. PMID: 33074246 Free PMC article.
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M, Le Vu P, Coutzac C, Marcheteau E, Béal C, Terme M, Gey A, Morisseau S, Teppaz G, Boselli L, Jacques Y, Béchard D, Tartour E, Cassard L, Chaput N. Desbois M, et al. Among authors: teppaz g. J Immunol. 2016 Jul 1;197(1):168-78. doi: 10.4049/jimmunol.1600019. Epub 2016 May 23. J Immunol. 2016. PMID: 27217584